Today, July 22nd, a virtual summit was hosted by KidneyX to announce the six winners of the Redesign Dialysis Phase 2 prize. The goal of the Redesign Dialysis prize is to provide prize money for novel ideas and innovations that will lead to better outcomes for people with kidney diseases and eventually to a truly artificial kidney. The eventual artificial kidney and innovations made along the way will lead to better outcomes for individuals with kidney diseases and improve their quality of life by bypassing in-center hemodialysis.
The American Society of Nephrology (ASN) is troubled by the Trump Administration’s decision to require submission of hospital data on COVID-19 patients directly to the Department of Health and Human Services (HHS) instead of the Centers for Disease Control and Prevention (CDC). This decision raises serious questions about the transparency and credibility of the data as well as concerns that the move will prevent researchers, public health officials, and other stakeholders from accessing the data to make projections and crucial decisions.
As the threat of COVID-19 was emerging in the United States, ASN and the broader kidney community participated in an effort organized by the Department of Health and Human Services (HHS) to develop policy recommendations that address the effects of COVID-19 on kidney patients and kidney care professionals.
The workgroups discussed and prioritized nearly 300 COVID-19-related kidney policy recommendations across seven key issue areas. HHS has already instituted many of the recommendations ASN and other stakeholders in the community made, and the society continues to work closely with the community to advocate for the policy recommendations to improve the care of kidney patients and protect the kidney care professionals that care for them.
On April 16, 2020, the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) published two notices (NOT-DK-20-023, NOT-DK-20-024) that made a significant and startling announcement. NIDDK announced the Division of Kidney, Urologic, & Hematologic Diseases (KUH’s) will no longer participate in the traditional National Institutes of Health (NIH) National Research Service Award (NRSA) T32 Program, and will instead participate in a new Institutional Training Program.
The Centers for Medicare and Medicaid Services (CMS) released the proposed rule for the 2021 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Incentive Program (QIP) on July 6. The proposed rule contains some of the nuts and bolts that run the Medicare ESRD program on the facility side. It contains numerous guardrails to protect kidney failure patients and provide them access to the best modalities.
When a novel coronavirus emerged in late 2019, everyone risked infection, but kidney patients found themselves especially vulnerable. People with kidney disease have compromised immune systems and the vast majority of these individuals—roughly half a million people—must visit dialysis centers several times a week, exposing themselves to contact with staff and other patients when they should ideally be isolated at home.
On July 2, the American Society of Nephrology (ASN) and the National Kidney Foundation (NKF) released a joint statement announcing the establishment of a joint task force that aims to reassess the includsion of race in diagnosing kidney diseases.
"Of the more than 37 million people affected by kidney diseases in the United States, a disproportionate number are of African American, Hispanic, Asian, and Native American descent. African Americans are three times more likely than Non-Hispanic Whites to experience kidney failure. Such disparities go beyond the high prevalence of kidney diseases and extend into differences in treatment modality, including access to transplantation. While African Americans represent 35% of people receiving dialysis in the United States, they are less likely to be identified as kidney transplant candidates when compared to Non-Hispanic White," begins the statment.